Leah N Klapper, PhD
Leah Klapper has been leading research and development in biotech start-ups for close to 20 years focusing on the advancement of academic programs from discovery to clinical proof of concept. Before joining FutuRx as CTO Leah served as CSO of Regenovation Ltd., a company developing acellular novel materials for in-situ tissue regeneration.
Prior to joining Regenovation Leah served as CSO of BioLineRx Ltd., a leading public drug development company, as General Manager of Bioline Innovations Jerusalem; an innovative biotechnology incubator and as Vice President of Research and Development at CureTech Ltd., a company developing novel immune-modulating molecules.
Leah gained her post-doctoral training at the Fred Hutchinson Cancer Research Center in Seattle Washington in the fields of translational medicine and immune-therapeutics, and holds a PhD in Immunology and Molecular Biology from the Weizmann Institute of Science in Rehovot Israel.